|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buettner R, Wolf J and Thomas RK: Lessons
learned from lung cancer genomics: The emerging concept of
individualized diagnostics and treatment. J Clin Oncol.
31:1858–1865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Normanno N, Maiello MR and De Luca A:
Epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs): Simple drugs with a complex mechanism of action? J
Cell Physiol. 194:13–19. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hosgood HD III, Pao W, Rothman N, Hu W,
Pan YH, Kuchinsky K, Jones KD, Xu J, Vermeulen R, Simko J, et al:
Driver mutations among never smoking female lung cancer tissues in
China identify unique EGFR and KRAS mutation pattern associated
with household coal burning. Respir Med. 107:1755–1762. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B,
Han X, Tian W, Pao W, Chen H, et al: Lung adenocarcinoma from East
Asian never-smokers is a disease largely defined by targetable
oncogenic mutant kinases. J Clin Oncol. 28:4616–4620. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wong DW, Leung EL, So KK, Tam IY, Sihoe
AD, Cheng LC, Ho KK, Au JS, Chung LP and Wong Pik M: University of
Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is
involved in various histologic types of lung cancers from
nonsmokers with wild-type EGFR and KRAS. Cancer. 115:1723–1733.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rikova K, Guo A, Zeng Q, Possemato A, Yu
J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al: Global survey
of phosphotyrosine signaling identifies oncogenic kinases in lung
cancer. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takeuchi K, Choi YL, Togashi Y, Soda M,
Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, et al:
KIF5B-ALK, a novel fusion oncokinase identified by an
immunohistochemistry-based diagnostic system for ALK-positive lung
cancer. Clin Cancer Res. 15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siegelin MD and Borczuk AC: Epidermal
growth factor receptor mutations in lung adenocarcinoma. Lab
Invest. 94:129–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Wang S, Xu S, Qu J and Liu B:
Clinicopathologic features of patients with non-small cell lung
cancer harboring the EML4-ALK fusion gene: A meta-analysis. PLoS
One. 9:e1106172014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
